End-of-day quote
Pakistan S.E.
06:00:00 2024-04-28 pm EDT
|
5-day change
|
1st Jan Change
|
254.5
PKR
|
+0.98%
|
|
+3.88%
|
+50.58%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
30,986
|
25,454
|
30,015
|
31,035
|
28,217
|
19,185
|
Enterprise Value (EV)
1 |
29,684
|
26,338
|
30,139
|
29,139
|
25,129
|
15,905
|
P/E ratio
|
43.8
x
|
29
x
|
23.9
x
|
24.6
x
|
13.2
x
|
59
x
|
Yield
|
1.54%
|
1.88%
|
1.95%
|
1.89%
|
-
|
-
|
Capitalization / Revenue
|
3.73
x
|
1.71
x
|
1.84
x
|
1.56
x
|
1.17
x
|
0.7
x
|
EV / Revenue
|
3.58
x
|
1.77
x
|
1.85
x
|
1.47
x
|
1.04
x
|
0.58
x
|
EV / EBITDA
|
29
x
|
14.9
x
|
14.2
x
|
14.1
x
|
7.84
x
|
11.9
x
|
EV / FCF
|
56.9
x
|
-66.6
x
|
26.9
x
|
12.1
x
|
18.3
x
|
23.5
x
|
FCF Yield
|
1.76%
|
-1.5%
|
3.72%
|
8.25%
|
5.46%
|
4.26%
|
Price to Book
|
13.5
x
|
8.13
x
|
6.67
x
|
6.01
x
|
4.2
x
|
2.72
x
|
Nbr of stocks (in thousands)
|
95,550
|
95,550
|
117,055
|
117,055
|
117,055
|
117,055
|
Reference price
2 |
324.3
|
266.4
|
256.4
|
265.1
|
241.1
|
163.9
|
Announcement Date
|
3/8/18
|
4/2/19
|
4/29/20
|
3/31/21
|
2/28/22
|
4/6/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
8,298
|
14,875
|
16,317
|
19,846
|
24,163
|
27,507
|
EBITDA
1 |
1,024
|
1,773
|
2,115
|
2,067
|
3,204
|
1,335
|
EBIT
1 |
1,001
|
1,562
|
1,884
|
1,799
|
2,903
|
1,010
|
Operating Margin
|
12.06%
|
10.5%
|
11.54%
|
9.06%
|
12.01%
|
3.67%
|
Earnings before Tax (EBT)
1 |
1,171
|
1,463
|
1,700
|
1,774
|
3,016
|
992.8
|
Net income
1 |
706.8
|
1,075
|
1,258
|
1,262
|
2,134
|
325.4
|
Net margin
|
8.52%
|
7.22%
|
7.71%
|
6.36%
|
8.83%
|
1.18%
|
EPS
2 |
7.397
|
9.180
|
10.74
|
10.78
|
18.23
|
2.780
|
Free Cash Flow
1 |
521.9
|
-395.3
|
1,120
|
2,404
|
1,373
|
676.8
|
FCF margin
|
6.29%
|
-2.66%
|
6.86%
|
12.11%
|
5.68%
|
2.46%
|
FCF Conversion (EBITDA)
|
50.96%
|
-
|
52.94%
|
116.3%
|
42.84%
|
50.71%
|
FCF Conversion (Net income)
|
73.83%
|
-
|
89.04%
|
190.49%
|
64.31%
|
208%
|
Dividend per Share
2 |
5.000
|
5.000
|
5.000
|
5.000
|
-
|
-
|
Announcement Date
|
3/8/18
|
4/2/19
|
4/29/20
|
3/31/21
|
2/28/22
|
4/6/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
884
|
124
|
-
|
-
|
-
|
Net Cash position
1 |
1,302
|
-
|
-
|
1,895
|
3,088
|
3,281
|
Leverage (Debt/EBITDA)
|
-
|
0.4989
x
|
0.0587
x
|
-
|
-
|
-
|
Free Cash Flow
1 |
522
|
-395
|
1,120
|
2,404
|
1,373
|
677
|
ROE (net income / shareholders' equity)
|
36.3%
|
35%
|
30.2%
|
26.1%
|
35.9%
|
4.73%
|
ROA (Net income/ Total Assets)
|
18.4%
|
16.4%
|
13.9%
|
11.3%
|
14.6%
|
4.36%
|
Assets
1 |
3,849
|
6,554
|
9,045
|
11,202
|
14,610
|
7,455
|
Book Value Per Share
2 |
24.00
|
32.80
|
38.40
|
44.10
|
57.40
|
60.20
|
Cash Flow per Share
2 |
11.50
|
6.040
|
5.500
|
18.20
|
21.00
|
21.40
|
Capex
1 |
28.4
|
315
|
525
|
851
|
543
|
503
|
Capex / Sales
|
0.34%
|
2.12%
|
3.22%
|
4.29%
|
2.25%
|
1.83%
|
Announcement Date
|
3/8/18
|
4/2/19
|
4/29/20
|
3/31/21
|
2/28/22
|
4/6/23
|
|
1st Jan change
|
Capi.
|
---|
| +50.58% | 107M | | +19.27% | 43.75B | | +27.47% | 22.06B | | +15.26% | 14.46B | | +12.33% | 13.62B | | +38.36% | 11.61B | | -9.54% | 6.9B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +9.64% | 5.32B |
Generic Pharmaceuticals
|